• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,378.32
  • 0.93 %
  • $352.22
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Aurinia Pharmaceuticals Inc. (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals Inc. (AUPH) Stock Price, News & Analysis

Currency in USD Disclaimer

$8.77

$0.53

(6.43%)

Day's range
$8.3
Day's range
$8.83
50-day range
$6.64
Day's range
$8.83
  • Country: CA
  • ISIN: CA05156V1022
52 wk range
$4.71
Day's range
$9.74
  • CEO: Mr. Peter S. Greenleaf M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 3.28
  • Piotroski Score 4.00
  • Grade Overweight
  • Symbol (AUPH)
  • Company Aurinia Pharmaceuticals Inc.
  • Price $8.77
  • Changes Percentage (6.43%)
  • Change $0.53
  • Day Low $8.30
  • Day High $8.83
  • Year High $9.74

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/13/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $12.00
  • High Stock Price Target $13.00
  • Low Stock Price Target $6.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.43
  • Trailing P/E Ratio -12.33
  • Forward P/E Ratio -12.33
  • P/E Growth -12.33
  • Net Income $-78,020,000

Income Statement

Quarterly

Annual

Latest News of AUPH

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Aurinia Pharmaceuticals Inc. Frequently Asked Questions

  • What were the earnings of AUPH in the last quarter?

    In the last quarter Aurinia Pharmaceuticals Inc. earnings were on Thursday, November, 7th. The Aurinia Pharmaceuticals Inc. maker reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09.

  • What is the Aurinia Pharmaceuticals Inc. stock price today?

    Today's price of Aurinia Pharmaceuticals Inc. is $8.77 — it has increased by +6.43% in the past 24 hours. Watch Aurinia Pharmaceuticals Inc. stock price performance more closely on the chart.

  • Does Aurinia Pharmaceuticals Inc. release reports?

    Yes, you can track Aurinia Pharmaceuticals Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Aurinia Pharmaceuticals Inc. stock forecast?

    Watch the Aurinia Pharmaceuticals Inc. chart and read a more detailed Aurinia Pharmaceuticals Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Aurinia Pharmaceuticals Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Aurinia Pharmaceuticals Inc. stock ticker.

  • How to buy Aurinia Pharmaceuticals Inc. stocks?

    Like other stocks, AUPH shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Aurinia Pharmaceuticals Inc.'s EBITDA?

    Aurinia Pharmaceuticals Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Aurinia Pharmaceuticals Inc.’s financial statements.

  • What is the Aurinia Pharmaceuticals Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.4445254767, which equates to approximately -44.45%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Aurinia Pharmaceuticals Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Aurinia Pharmaceuticals Inc.'s financials relevant news, and technical analysis. Aurinia Pharmaceuticals Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Aurinia Pharmaceuticals Inc. stock currently indicates a “sell” signal. For more insights, review Aurinia Pharmaceuticals Inc.’s technical analysis.

  • A revenue figure for Aurinia Pharmaceuticals Inc. for its last quarter?

    Aurinia Pharmaceuticals Inc. published it's last quarterly revenues at $55.50 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.